PMID- 35531134
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1735-5362 (Print)
IS  - 1735-9414 (Electronic)
IS  - 1735-5362 (Linking)
VI  - 17
IP  - 3
DP  - 2022 Jun
TI  - Investigation of the relationship between miR-33a, miR-122, erythrocyte membrane 
      fatty acids profile, and serum lipids with components of metabolic syndrome in 
      type 2 diabetic patients.
PG  - 242-251
LID - 10.4103/1735-5362.343078 [doi]
AB  - BACKGROUND AND PURPOSE: MicroRNAs (miRNAs) are small non-coding RNA molecules 
      acting as critical regulators of post-transcriptional gene expression. MiR-33a 
      and miR-122 have a crucial role in cholesterol and lipid metabolism. Therefore, 
      their dysregulation may contribute to metabolic abnormality and their inhibition 
      may be a useful therapeutic strategy. The objective of the present study was to 
      investigate the relationship between miR-33a, miR-122, erythrocyte membrane fatty 
      acids profile, and serum lipids with components of metabolic syndrome in an 
      Iranian population suffering from type 2 diabetes mellitus (T2DM). EXPERIMENTAL 
      APPROACH: Expression of miR-33a and miR-122 was measured by real-time polymerase 
      chain reaction and erythrocyte membrane fatty acid profiles were analyzed by gas 
      chromatography-mass spectrometry. FINDINGS/RESULTS: T2DM patients with and 
      without metabolic syndrome had significantly higher miR-33a and miR-122 levels 
      compared to controls. MiRNAs were significantly correlated with saturated fatty 
      acid (SFAs), total SFAs/total polyunsaturated fatty acids (PUFAs) ratio, fasting 
      plasma glucose, triacylglycerols, insulin and homeostatic model assessment of 
      insulin resistance. In addition, there was a significant negative correlation 
      between miR-33a and miR-122 levels and PUFAs, total PUFAs/total SFAs ratio and 
      omega 6 fatty acids. CONCLUSION AND IMPLICATIONS: Considering the roles of 
      miR-33a and miR-122 in cholesterol and lipids metabolism, it may be concluded 
      that the measurement of their expression may be useful as a potential additional 
      biomarker for cardiometabolic derangement in T2DM patients. In addition, these 
      findings may suggest that the inhibition of these miRNAs by anti-miRNA therapies 
      may be explored as a potential therapeutic strategy.
CI  - Copyright: (c) 2022 Research in Pharmaceutical Sciences.
FAU - Masoudi, Fatemeh
AU  - Masoudi F
AD  - Department of Clinical Biochemistry and Bioinformatics Research Center, School of 
      Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, 
      Isfahan, I.R. Iran.
FAU - Sharifi, Mohammad Reza
AU  - Sharifi MR
AD  - Department of Genetics and Molecular Biology, School of Medicine, Isfahan 
      University of Medical Sciences, Isfahan, I.R. Iran.
FAU - Pourfarzam, Morteza
AU  - Pourfarzam M
AD  - Department of Clinical Biochemistry and Bioinformatics Research Center, School of 
      Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, 
      Isfahan, I.R. Iran.
LA  - eng
PT  - Journal Article
DEP - 20220418
PL  - Iran
TA  - Res Pharm Sci
JT  - Research in pharmaceutical sciences
JID - 101516968
PMC - PMC9075026
OTO - NOTNLM
OT  - Erythrocyte membrane fatty acid profile
OT  - Metabolic syndrome
OT  - Type 2 diabetes
OT  - miR-122
OT  - miR-33a
COIS- The authors declared no conflicts of interest in this study.
EDAT- 2022/05/10 06:00
MHDA- 2022/05/10 06:01
PMCR- 2022/04/18
CRDT- 2022/05/09 04:30
PHST- 2021/09/15 00:00 [received]
PHST- 2021/11/06 00:00 [revised]
PHST- 2021/12/08 00:00 [accepted]
PHST- 2022/05/09 04:30 [entrez]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/05/10 06:01 [medline]
PHST- 2022/04/18 00:00 [pmc-release]
AID - RPS-17-242 [pii]
AID - 10.4103/1735-5362.343078 [doi]
PST - epublish
SO  - Res Pharm Sci. 2022 Apr 18;17(3):242-251. doi: 10.4103/1735-5362.343078. 
      eCollection 2022 Jun.